LumiQuick Showcases Expanded Testing Portfolio at MEDICA 2025

LumiQuick Diagnostics, Inc. is showcasing its comprehensive range of rapid tests and immunoassay solutions at MEDICA 2025 from 17 to 20 November in Düsseldorf, Germany. Exhibiting in Hall 3, Stand D25-4, the company is presenting its newest developments across infectious-disease testing, drugs-of-abuse screening, cardiac and tumor markers, fertility and vitamin D assays.

LumiQuick’s exhibitor profile emphasizes its QuickProfile rapid-test lines, designed for point-of-care and laboratory use. The infectious-disease portfolio includes assays for malaria, dengue, Zika, chikungunya, influenza A/B, H. pylori, adenovirus, rotavirus, HIV, syphilis, and more, serving both tropical-disease settings and routine clinical workflows. The company’s QuickProfile portfolio also includes rapid tests for cardiac markers, cancer markers, and fertility hormones.

A major focus of the company is its extensive drugs-of-abuse (DOA) collection. The QuickProfile DOA lineup includes single test strips, single-drug card tests, multi-drug panels, and multi-panel cups that detect methamphetamine, cocaine, opiates, THC, fentanyl, synthetic cannabinoids, and many other substances.

At MEDICA 2025, LumiQuick is also highlighting the recently added Aoxre OxisResearch brand, which provides testing solutions for oxidative stress biomarkers, antioxidants, DNA damage, and related indicators. These products simplify the measurement of oxidative, antioxidant, nitrosative, and inflammatory biomarkers that play central roles in a wide range of diseases, including cancer, diabetes, cardiovascular disease, autism, atherosclerosis, stroke, Alzheimer’s, Parkinson’s, and other epidemiologic conditions.

Related Links:
Lumiquick Diagnostics, Inc.